Nebula Research & Development LLC Supernus Pharmaceuticals, Inc. Transaction History
Nebula Research & Development LLC
- $1.17 Trillion
- Q2 2025
A detailed history of Nebula Research & Development LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 12,429 shares of SUPN stock, worth $597,462. This represents 0.03% of its overall portfolio holdings.
Number of Shares
12,429Holding current value
$597,462% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
313Shares Held
61.7MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$500 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$298 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$231 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$145 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$133 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.57B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...